Kalbe Farma Tbk PT - Asset Resilience Ratio
Kalbe Farma Tbk PT (KLBF) has an Asset Resilience Ratio of 6.34% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KLBF total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Kalbe Farma Tbk PT's Asset Resilience Ratio has changed over time. See what is Kalbe Farma Tbk PT's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Kalbe Farma Tbk PT's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Kalbe Farma Tbk PT worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp1.72 Trillion | 5.84% |
| Short-term Investments | Rp148.38 Billion | 0.5% |
| Total Liquid Assets | Rp1.87 Trillion | 6.34% |
Asset Resilience Insights
- Limited Liquidity: Kalbe Farma Tbk PT maintains only 6.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Kalbe Farma Tbk PT Industry Peers by Asset Resilience Ratio
Compare Kalbe Farma Tbk PT's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096 |
Drug Manufacturers - General | 3.84% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 40.02% |
|
Sanofi
F:SNW2 |
Drug Manufacturers - General | 0.37% |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422 |
Drug Manufacturers - General | 3.76% |
|
Grifols S.A
F:G0FB |
Drug Manufacturers - General | 0.04% |
|
Eli Lilly and Company
NYSE:LLY |
Drug Manufacturers - General | 8.63% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
TTK Healthcare Limited
NSE:TTKHLTCARE |
Drug Manufacturers - General | 71.91% |
Annual Asset Resilience Ratio for Kalbe Farma Tbk PT (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Kalbe Farma Tbk PT.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 10.98% | Rp3.23 Trillion ≈ $189.32 Million |
Rp29.43 Trillion ≈ $1.72 Billion |
+3.30pp |
| 2023-12-31 | 7.68% | Rp2.08 Trillion ≈ $121.77 Million |
Rp27.06 Trillion ≈ $1.59 Billion |
-1.35pp |
| 2022-12-31 | 9.03% | Rp2.46 Trillion ≈ $144.18 Million |
Rp27.24 Trillion ≈ $1.60 Billion |
-4.93pp |
| 2021-12-31 | 13.96% | Rp3.58 Trillion ≈ $209.93 Million |
Rp25.67 Trillion ≈ $1.50 Billion |
+0.35pp |
| 2020-12-31 | 13.61% | Rp3.07 Trillion ≈ $179.97 Million |
Rp22.56 Trillion ≈ $1.32 Billion |
+2.48pp |
| 2019-12-31 | 11.13% | Rp2.26 Trillion ≈ $132.15 Million |
Rp20.26 Trillion ≈ $1.19 Billion |
-2.91pp |
| 2018-12-31 | 14.03% | Rp2.55 Trillion ≈ $149.23 Million |
Rp18.15 Trillion ≈ $1.06 Billion |
+1.26pp |
| 2017-12-31 | 12.78% | Rp2.12 Trillion ≈ $124.39 Million |
Rp16.62 Trillion ≈ $973.65 Million |
-3.45pp |
| 2016-12-31 | 16.22% | Rp2.47 Trillion ≈ $144.75 Million |
Rp15.23 Trillion ≈ $892.18 Million |
+15.09pp |
| 2015-12-31 | 1.14% | Rp155.75 Billion ≈ $9.13 Million |
Rp13.70 Trillion ≈ $802.56 Million |
-0.47pp |
| 2014-12-31 | 1.60% | Rp199.39 Billion ≈ $11.68 Million |
Rp12.43 Trillion ≈ $728.06 Million |
-0.05pp |
| 2013-12-31 | 1.66% | Rp187.74 Billion ≈ $11.00 Million |
Rp11.32 Trillion ≈ $663.02 Million |
-0.77pp |
| 2012-12-31 | 2.43% | Rp229.12 Billion ≈ $13.43 Million |
Rp9.42 Trillion ≈ $551.85 Million |
+1.06pp |
| 2011-12-31 | 1.38% | Rp113.87 Billion ≈ $6.67 Million |
Rp8.27 Trillion ≈ $484.86 Million |
+1.30pp |
| 2010-12-31 | 0.08% | Rp5.32 Billion ≈ $311.49K |
Rp7.03 Trillion ≈ $412.08 Million |
-0.89pp |
| 2009-12-31 | 0.97% | Rp62.60 Billion ≈ $3.67 Million |
Rp6.48 Trillion ≈ $379.85 Million |
-1.22pp |
| 2008-12-31 | 2.19% | Rp124.75 Billion ≈ $7.31 Million |
Rp5.70 Trillion ≈ $334.22 Million |
-1.23pp |
| 2007-12-31 | 3.42% | Rp175.83 Billion ≈ $10.30 Million |
Rp5.14 Trillion ≈ $301.08 Million |
-2.19pp |
| 2006-12-31 | 5.62% | Rp259.70 Billion ≈ $15.22 Million |
Rp4.62 Trillion ≈ $270.98 Million |
-13.44pp |
| 2005-12-31 | 19.06% | Rp882.99 Billion ≈ $51.74 Million |
Rp4.63 Trillion ≈ $271.50 Million |
-17.51pp |
| 2004-12-31 | 36.57% | Rp1.10 Trillion ≈ $64.65 Million |
Rp3.02 Trillion ≈ $176.78 Million |
+6.24pp |
| 2003-12-31 | 30.33% | Rp742.67 Billion ≈ $43.52 Million |
Rp2.45 Trillion ≈ $143.47 Million |
+15.45pp |
| 2002-12-31 | 14.88% | Rp299.97 Billion ≈ $17.58 Million |
Rp2.02 Trillion ≈ $118.10 Million |
+13.48pp |
| 2001-12-31 | 1.41% | Rp26.39 Billion ≈ $1.55 Million |
Rp1.88 Trillion ≈ $110.00 Million |
-5.44pp |
| 2000-12-31 | 6.84% | Rp120.31 Billion ≈ $7.05 Million |
Rp1.76 Trillion ≈ $103.00 Million |
-- |
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more